These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 17929214)

  • 1. [Rational use of catecholamines and inotropes].
    Hewing B; Stangl K
    Pneumologie; 2007 Nov; 61(11):700-8. PubMed ID: 17929214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of current and investigational pharmacologic agents for acute heart failure syndromes.
    Shin DD; Brandimarte F; De Luca L; Sabbah HN; Fonarow GC; Filippatos G; Komajda M; Gheorghiade M
    Am J Cardiol; 2007 Jan; 99(2A):4A-23A. PubMed ID: 17239703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New catecholamines in clinical cardiovascular medicine.
    Leier CV
    Kardiol Pol; 1980; 23(9):721-5. PubMed ID: 7441942
    [No Abstract]   [Full Text] [Related]  

  • 4. [Enoximone--clinical experiences in heart surgery].
    Krüger AD; Francke A; Emmrich K
    Anaesthesiol Reanim; 1996; 21(3):60-8. PubMed ID: 8766397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes.
    Bayram M; De Luca L; Massie MB; Gheorghiade M
    Am J Cardiol; 2005 Sep; 96(6A):47G-58G. PubMed ID: 16181823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
    Weber KT; Janicki JS; Jain MC
    J Heart Transplant; 1986; 5(2):105-12. PubMed ID: 2956397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacotherapy of severe heart failure with inodilators--new approaches].
    Baumann G; Hader O
    Z Kardiol; 1996; 85 Suppl 4():9-19. PubMed ID: 9027110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inotropes in the management of acute heart failure.
    Petersen JW; Felker GM
    Crit Care Med; 2008 Jan; 36(1 Suppl):S106-11. PubMed ID: 18158469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Positive inotropic substances in therapy of heart failure: digitalis, catecholamines, phosphodiesterase inhibitors].
    Stefenelli T
    Acta Med Austriaca; 1991; 18(4):81-5. PubMed ID: 1763582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of more than one inotrope in acute heart failure is associated with increased mortality: a multi-centre observational study.
    Rossinen J; Harjola VP; Siirila-Waris K; Lassus J; Melin J; Peuhkurinen K; Nieminen MS
    Acute Card Care; 2008; 10(4):209-13. PubMed ID: 18720087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inotropic therapy for cardiac low output syndrome: comparison of hemodynamic effects of dopamine/dobutamine versus dopamine/dopexamine.
    El Mokhtari NE; Arlt A; Meissner A; Lins M
    Eur J Med Res; 2007 Nov; 12(11):563-7. PubMed ID: 18024265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hemodynamic effects of amrinone, dobutamine and dopamine in the cardiac low output syndrome following open-heart surgery].
    Husedzinović I; Rumboldt Z; Ivancan V; Nikić N; Rudeź I; Biocina B; Sutlić Z
    Lijec Vjesn; 1995 Jun; 117 Suppl 2():32-4. PubMed ID: 8649147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of randomized clinical trials in acute heart failure syndromes.
    Teerlink JR
    Am J Cardiol; 2005 Sep; 96(6A):59G-67G. PubMed ID: 16181824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inotropic therapy for heart failure: an evidence-based approach.
    Felker GM; O'Connor CM
    Am Heart J; 2001 Sep; 142(3):393-401. PubMed ID: 11526351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Concept for therapy of heart failure in heart surgery].
    Zerkowski HR; Günnicker M; Marggraf G; Reidemeister JC
    Z Kardiol; 1994; 83 Suppl 2():55-61. PubMed ID: 8091825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of chronic heart failure with positive inotropic agents].
    Lechat P
    Therapie; 1989; 44(6):437-45. PubMed ID: 2576155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term intravenous inotropes in low-output terminal heart failure?
    von Scheidt W; Pauschinger M; Ertl G
    Clin Res Cardiol; 2016 Jun; 105(6):471-81. PubMed ID: 26879807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure.
    Elkayam U; Tasissa G; Binanay C; Stevenson LW; Gheorghiade M; Warnica JW; Young JB; Rayburn BK; Rogers JG; DeMarco T; Leier CV
    Am Heart J; 2007 Jan; 153(1):98-104. PubMed ID: 17174645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical use of inotropes in cardiac failure: dopamine, dobutamine, prenalterol and pirbuterol.
    Rae AP; Tweddel AC; Hutton I
    Herz; 1983 Feb; 8(1):23-33. PubMed ID: 6832690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving concepts in the treatment of heart failure: should new inotropic agents carry promise or paranoia?
    Young JB
    Pharmacotherapy; 1996; 16(2 Pt 2):78S-84S. PubMed ID: 8668609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.